FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma

Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing potential beyond MM, which encouraged us to develop new anti-CD38 mAbs to meet clinical needs....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guangbing, Guo, Cuiyu, Wang, Yan, Zhang, Xianda, Liu, Shuang, Qu, Wen, Chen, Chunxia, Yan, Lingli, Yang, Zhouning, Zhang, Zhixiong, Jiang, Xiaohua, Chen, Xiaofeng, Liu, Hong, Lai, Qinhuai, Wei, Xian, Lu, Ying, Zhao, Shengyan, Deng, Han, Wang, Yuxi, Yu, Lin, Yu, Hongbin, Wu, Yu, Su, Zhaoming, Chen, Pengyu, Ren, Ziqing, Yu, Meng, Qu, Feng, Luo, Yong, Gou, Lantu, Li, Qing, Huang, Ying, Ma, Fanxin, Yang, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798557/
https://www.ncbi.nlm.nih.gov/pubmed/36581954
http://dx.doi.org/10.1186/s13045-022-01395-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798557/
https://www.ncbi.nlm.nih.gov/pubmed/36581954
http://dx.doi.org/10.1186/s13045-022-01395-0

Ejemplares similares